Chemours (CC)
(Delayed Data from NYSE)
$19.44 USD
+0.10 (0.52%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $19.44 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.44 USD
+0.10 (0.52%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $19.44 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value F Growth D Momentum F VGM
Zacks News
Earnings Preview: Chemours (CC) Q2 Earnings Expected to Decline
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Chemours (CC) benefits from strong Opteon demand, effective execution, and its cost-reduction and pricing actions.
Chemours (CC) Stock Up 16% in 3 Months: What's Driving It?
by Zacks Equity Research
Chemours (CC) gains on healthy Opteon demand, strong execution and its cost-reduction and pricing actions.
Chemours (CC) Gains on Opteon Adoption Amid Demand Woes
by Zacks Equity Research
While Chemours (CC) is exposed to headwinds from demand softness in certain areas, it gains on continued Opteon adoption, strong execution and its cost-reduction and pricing actions.
Chemours (CC) to Divest Glycolic Acid Business to PureTech
by Zacks Equity Research
Chemours (CC) believes that its Glycolic Acid portfolio complements PureTech's growth strategy.
Strength Seen in Chemours (CC): Can Its 24.1% Jump Turn into More Strength?
by Zacks Equity Research
Chemours (CC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why You Should Hold Onto Chemours (CC) Stock for Now
by Zacks Equity Research
While Chemours (CC) is exposed to headwinds from demand weakness in certain businesses, it gains on healthy Opteon adoption and its pricing actions.
Chemours (CC) Extends Capacity to Meet Customers' Needs
by Zacks Equity Research
Chemours (CC) offers a portfolio of HFO-1336mzzZ-based products that are more environmentally friendly than non-HFO alternatives.
Chemours' (CC) Q1 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Lower volumes and currency headwinds on a year-over-year basis, partly offset by higher pricing, impact Chemours' (CC) results in the first quarter.
Are Investors Undervaluing Chemours (CC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemours (CC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Chemours (CC) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Chemours (CC) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 58.06% and 0.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Methanex (MEOH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Methanex (MEOH) delivered earnings and revenue surprises of 20.65% and 6.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Northern Technologies (NTIC) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Northern Technologies (NTIC) delivered earnings and revenue surprises of -44.44% and 10.44%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold Onto Chemours (CC) Stock for Now
by Zacks Equity Research
While Chemours (CC) is exposed to headwinds from higher raw material costs, it gains on healthy Opteon demand and its pricing actions.
Chemours (CC) Posts Break-Even Q4 Earnings, Sales Miss
by Zacks Equity Research
Chemours (CC) gains from increased prices across its segments amid headwinds from higher input cost inflation, adverse currency movements and soft demand in Europe & Asia in Q4.
Chemours (CC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Chemours (CC) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Chemours (CC) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of -100% and 5.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
FMC (FMC) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
FMC (FMC) delivered earnings and revenue surprises of 2.16% and 7.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Chemours (CC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Albemarle (ALB) Up 0.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Albemarle (ALB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours (CC) Gains on Opteon Demand Amid Input Cost Woes
by Zacks Equity Research
While Chemours (CC) is exposed to headwinds from higher raw material costs, it gains on healthy Opteon demand, strong execution and its cost-reduction and pricing actions.
Chemours (CC) Earnings and Revenues Top Estimates in Q3
by Zacks Equity Research
Higher prices contribute favorably to Chemours' (CC) top line growth in the third quarter.
New Strong Sell Stocks for October 26th
by Zacks Equity Research
HES, JRVR and CC have been added to the Zacks Rank #5 (Strong Sell) List on October 26, 2022.